revakinagene taroretcel
Trade name: Encelto
Recombinant proteinapprovedOrphan Drug FDA
Approved
Mar 5, 2025
Ciliary neurotrophic factor is a protein that in humans is encoded by the CNTF gene. — Wikipedia
Clinical trial activity
18 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
13
Phase 3
3
Phase 4
1
Earliest trial started Jun 1, 2003 (NCT00063765)
Timeline
Indications
Approved for
Mechanism of action
- Ciliary neurotrophic factorSupplementation
CNTF supplementation
Approval history
- approvedMar 5, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCiliary neurotrophic factor ↗
- NCATS0YMN57H314 ↗
- ChEMBLCHEMBL5314636 ↗
- ChEMBLCHEMBL4298063 ↗
Also known as
- ciliary neurotrophic factor
- ciliary neurotrophic factor
- ciliary neurotrophic factor (human)
- human ciliary neurotrophic factor
- human cntf
- nt-501
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06971939 | Phase 4 | Aug 15, 2025 | Neurotech Pharmaceuticals |
| NCT06397131 | Phase 3 | Apr 1, 2025 | Neurotech Pharmaceuticals |
| NCT04729972 | Phase 2 | Mar 1, 2021 | Neurotech Pharmaceuticals, The EMMES Corporation, The Lowy Medical Research Institute Limited |
| NCT04577300 | Phase 2 | Oct 15, 2020 | Stanford University |
| NCT03319849 | Phase 3 | Feb 6, 2018 | National Eye Institute (NEI), Neurotech Pharmaceuticals |
| NCT03316300 | Phase 3 | Nov 24, 2017 | National Eye Institute (NEI), Neurotech Pharmaceuticals |
| NCT03071965 | Phase 2 | May 12, 2017 | Neurotech Pharmaceuticals |
| NCT02862938 | Phase 2 | Jun 1, 2016 | Stanford University |
| NCT01949324 | Phase 2 | Apr 1, 2014 | Duke University, Neurotech Pharmaceuticals, The EMMES Corporation, The Lowy Medical Research Institute Limited |
| NCT01648452 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | National Eye Institute (NEI), National Institutes of Health (NIH) |
| NCT01530659 | Phase 2 | Jan 1, 2012 | Food and Drug Administration, Neurotech Pharmaceuticals, University of California, San Francisco |
| NCT01327911 | Phase 1 | May 1, 2011 | Neurotech Pharmaceuticals, Neurotech USA, The Lowy Medical Research Institute Limited |
| NCT01411657 | Phase 1 | Apr 1, 2011 | Stanford University |
| NCT01408472 | Phase 1 | Apr 1, 2011 | Stanford University, University of Miami |
| NCT00447954 | Phase 2 | Jan 1, 2007 | Neurotech Pharmaceuticals |
| NCT00447993 | Phase 2 | Jan 1, 2007 | Neurotech Pharmaceuticals |
| NCT00447980 | Phase 2 | Jan 1, 2007 | Neurotech Pharmaceuticals |
| NCT00063765 | Phase 1 | Jun 1, 2003 | National Eye Institute (NEI) |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurotech Pharmaceuticals | For profit | 12 | 12 | 4 | 2007 |
| National Eye Institute (NEI) | Government | 4 | 2 | 3 | 2003 |
| Stanford University | Academic/Hospital | 4 | 4 | 2 | 2011 |
| The Lowy Medical Research Institute Limited | Academic/Hospital | 3 | 0 | 2 | 2011 |
| The EMMES Corporation | For profit | 2 | 0 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2012 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2012 |
| Neurotech USA | For profit | 1 | 0 | 1 | 2011 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2011 |
11 organizations
Page 1 / 1